Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information 5f. WORK UNIT NUMBER The objective of this project was to create genetically engineered mouse (GEM) models that in addition to developing ovarian carcinomas similar to human endometrioid carcinomas, also express a reporter for Caspase-3 activity, a hallmark of cells undergoing apoptosis. During the three year funding period, we generated stable lines of transgenic mice carrying a Cre-inducible luciferase reporter or apoptosis reporter and verified function of the reporter transgenes in vivo. Using Apcflox/flox;Ptenflox/flox;ROSA26LSL-Luc/+ and Apcflox/flox;Ptenflox/flox; ApoptosisLSL-Luc mice generated as part of this project, we confirmed that BLI can be used to monitor ovarian tumor progression and drug response in vivo. In addition, we showed that Apcflox/flox;Ptenflox/flox;ApoptosisLSL-Luc mice can be used to image treatment-dependent induction of apoptosis. Efficacy of a targeted therapeutic agent (Akt inhibitor, Perifosine), alone and in combination with a standard chemotherapeutic agent (Cisplatin) was evaluated. Our studies revealed that combination therapy resulted in enhanced levels of apoptosis compared to either agent alone, and suggest this may be a promising approach for treating women with advanced stage ovarian endometrioid adenocarcinomas with PI3K/Akt/mTOR signaling pathway defects. ovarian endometrioid adenocarcinoma, transgenic mouse model, functional imaging reporter 27
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INTRODUCTION:
A goal of ovarian cancer research is to identify "hallmark" genetic alterations that characterize each major histological subtype of ovarian carcinoma and to develop novel therapeutics that target the signaling pathways deregulated by these molecular defects. Ideally, "personalized" therapeutic regimens could be designed based on the specific molecular alterations present in a given patient's tumor. Molecular data collected over the last several years have led to better comprehension of cancer pathogenesis and the mechanisms by which deregulated signaling pathways contribute to tumor development and progression. These pathways offer novel therapeutic 'targets' (e.g. Akt) for 'lead molecules' designed to inhibit the signaling derived from these pathways. Our ability to efficiently translate new therapies from the laboratory bench into the patient would be greatly enhanced by the availability of animal models that could be used to test efficacy of new drugs, evaluate their toxicity, and identify the best route of administration, dose, and schedule. Only limited information can be obtained from the response of cancer cells in culture or implanted (xenografted) into immunocompromised mice. Although there are many new drugs and possible combinations of drugs available today, identification of the most efficacious of these remains a major challenge and a rate-limiting process that cannot easily be conducted in women with the disease. Molecular imaging technologies have the potential to enhance preclinical studies conducted in animal models of cancer. As imaging methods are non-invasive, they allow for longitudinal studies in a single animal. Moreover, molecular imaging can increase the statistical significance of a study, allow for more clinically relevant study designs and decrease the number of animals required. Imaging in live animals can also provide important information on the optimal route of delivery, timing, and dosing of drugs. Dr. Cho's group has developed a mouse model of ovarian endometrioid adenocarcinoma, based on conditional deletion of Apc and Pten, which shows morphological features, biological behavior, and gene expression profiles similar to human endometrioid adenocarcinomas with the same signaling pathway defects 1 . In parallel, Dr. Rehemtulla's group has developed several molecular imaging strategies for non-invasive monitoring of Akt kinase activity as well as Caspase-3 proteolytic activity in live animals 2, 3 . The objective of this project is to combine these two technologies to create genetically engineered mouse (GEM) models that in addition to developing ovarian carcinomas, will also express either a reporter for Akt activity, a major survival signal, or for Caspase-3 activity, a hallmark of cells undergoing apoptosis. We hypothesize that tumors arising in our GEM model of ovarian cancer will respond to drugs that target the specific molecular defects present in the tumor cells, and that response to different drug regimens can be monitored quantitatively and non-invasively in live animals.
BODY:
As described below, we have completed nearly all of the tasks outlined in the Statement of Work (SOW) proposed in our original application. The laboratories of the Initiating PI (Cho) and Partnering (Rehemtulla) PI have worked very closely together to complete the majority of the tasks outlined in the SOW, and hence, progress from both labs during the three year funding period will be summarized below with specific contributions of each lab toward individual tasks clearly indicated. Our studies have emphasized work with the mice carrying these reporter transgenes were successfully generated relatively early in the funding period. A detailed description of studies performed toward completion of the specific tasks in the SOW is provided below: Aim 1: Construction of transgenic mice wherein conditional deletion of Apc and Pten occurs with simultaneous expression of molecular imaging reporters for Akt or Apoptosis.
Summary of research accomplishments associated with each task outlined in the approved
(i) Construction of reporter transgenic mice: As described in our Annual Reports for years 1 and 2, we proposed to construct two transgenic mice strains wherein expression of a molecular imaging reporter (Apoptosis or Akt) as well as an internal control can be activated in a Cre dependent manner. The Rehemtulla laboratory designed the transgene constructs to contain the EF-1 (PEF) promoter which drives transcription of the tomato (fluorescent protein) coding sequence. The presence of a transcription stop site and poly-adenylation target site (pA) at the end of the tomato coding sequence result in termination of transcription such that only the tomato protein is expressed. In the presence of Cre recombinase (ectopically expressed), recombination of the loxP sequences would result in deletion of the tomato coding sequence as well as the adjoining pA sequences. In this "floxed" form, the transgene results in transcription of the molecular imaging (Akt or apoptosis) firefly luciferase reporter as well as an IRES (internal ribosome entry site) and the renilla luciferase (rluc) coding sequence (Figure 1 ). mice. Tumorbearing mice or murine OEA-derived cell lines were treated with cisplatin and paclitaxel, mTOR inhibitor rapamycin, or AKT inhibitors API-2 or perifosine. Treatment effects were monitored in vivo by tumor volume measurements and bioluminescence imaging, in vitro by WST-1 proliferation assays, and in OEA tissues and cells by immunoblotting and immunostaining for levels and phosphorylation status of PI3K/AKT/mTOR signaling pathway components. We found that murine OEAs responded to cisplatin and paclitaxel, rapamycin, and AKT inhibitors in vivo. In vitro studies showed that response to mTOR and AKT inhibitors, but not conventional cytotoxic drugs, was dependent on the status of PI3K/AKT/mTOR signaling. We also found that AKT inhibition in APC-/PTEN-tumor cells resulted in compensatory up-regulation of ERK signaling, suggesting that multiple rather than single agent targeted therapy will be more efficacious for treating ovarian cancers. The studies clearly demonstrate the utility of this GEM model of ovarian cancer for preclinical testing of novel PI3K/AKT/mTOR signaling inhibitors. Methodological details and data figures are provided in the attached page proofs.
Aim 3: Optimization of combination therapies using molecular imaging. Anti-cancer drug discovery efforts are aimed at selecting, from a vast number of candidate compounds, those that most safely and effectively eradicate the disease. Moreover, given the overwhelming number of possible combination therapies that can be considered for evaluation in clinical trials, animal model systems can be used to identify those multi-drug regimens with greatest promise for efficacy in humans. In Specific Aim 3 we had proposed to use molecular imaging to identify the most efficacious combination therapy. Since platinum-based agents (Carbo-and Cisplatin) are the standard of care for ovarian cancer, we wanted to investigate if inhibition of the key survival signaling pathway (i.e. the PI-3-Kinase/Akt pathway) would enhance the efficacy of these platinum-based chemotherapies. Indeed, results presented in the figures below demonstrate that the ability to image apoptosis provides proof that the combination therapy has enhanced efficacy compared to single agents alone. Tumorbearing mice that were also expressing the Apoptosis reporter were treated with Cisplatin 5mg/kg/, and Perifosine (10mg/kg/). In contrast to the Control group (untreated, right) the combination therapy (left) resulted in a more then additive increase in apoptosis suggesting that the combination therapy will be more efficacious. Figure 3 below provides for results wherein imaging of apoptosis was carried out on animals treated with the single agents as well as combination therapy dynamically over time.
These results demonstrate that Cisplatin treatment alone resulted in some induction of apoptosis, while Perifosine treatment alone resulted in a significantly more enhanced levels of apoptosis on the first five days of treatment which subsided for the following five days (days 8--12). We believe this may represent the development of resistance to the drug. Interestingly, when the animals were treated with Cisplatin and Perifosine in combination, the tumors continued to undergo apoptosis on days 8--12 and in fact, the level of apoptosis was significantly more robust. These results support our hypothesis that the combination therapy would be more efficacious than either agent alone. Tumor-bearing animals that also express the Apoptosis LSL-Luc reporter were used to evaluate the efficacy of combining an Akt--inhibitor (Perifosine) with Cisplatin. Control group was treated with PBS. The Perifosine group was treated with 10mg/kg Perifosine, 5 times a week for two weeks; The Cisplatin group was treated with 5mg/kg cisplatin given twice a week; combination group was treated with 5mg/kg cisplatin twice a week (circles) and 10mg/kg perifosine, 5 times a week for two weeks (box). Animals were monitored for 3 weeks after completion of therapy. Bioluminescence signals were monitored 5 times a week 6 hours after treatment. Averages of fold of increase in bioluminescence signals are plotted upon normalization to tumor volume change and error bars represent SEM. 
KEY RESEARCH ACCOMPLISHMENTS:
• 
CONCLUSIONS:
We have generated mice that are transgenic for two different imaging reporters (Rosa26 LSL-Luc/+ and Apoptosis LSL-Luc ) that also carry floxed Pten and Apc alleles. Ovarian bursal injection of AdCre in these animals induces tumor formation and activation of the luciferase reporter alleles. We have shown that Apc flox/flox ;Pten flox/flox ;Apoptosis LSL-Luc mice can be used to image treatment-dependent induction of apoptosis. Efficacy of a targeted therapeutic agent (Akt inhibitor, Perifosine), alone and in combination with a standard chemotherapeutic agent (Cisplatin) was evaluated. Our studies revealed that combination therapy resulted in enhanced levels of apoptosis compared to either agent alone. Interestingly, although Cisplatin as a single agent was not able to induce apoptosis as robustly as Perifosine, in studies wherein tumor volumes were determined by MRI, Cisplatin was able to induce significantly enhanced tumor control compared to Perifosine as a single agent. These results suggest that Cisplatin, which is a DNA damaging agent, may induce tumor cell kill primarily through nonapoptotic mechanisms.
Based on the data we've collected, we believe that future studies of Cisplatin response should evaluate levels of non-apoptotic death (e.g autophagy) in addition to apoptosis. Autophagy is an alternative mode of cell demise, representing a self-cannibalization process that involves sequestration of cell structures in double-membraned organelles, called autophagosomes. The physiological role of autophagy is to remove long-lived proteins and damaged organelles, but when it is extensive, activated inappropriately or in cells which are unable to die by apoptosis, autophagy acts as an alternative celldeath pathway. It has been proposed that tumor cells in some conditions might employ autophagy as a mechanism to evade therapy-induced death. It has recently been shown that cisplatin-triggered autophagy partially protects primary renal tubular epithelial cells from concomitant induction of apoptotic cell death by the drug [Kaushal et. al., 2008] . Therefore, the ability of combined Cisplatin and Perifosine therapy to drive cells to undergo apoptosis may in the long run mechanistically delay recurrence of OEA compared to Cisplatin alone. Validation of this hypothesis would require specifically designed studies.
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Translational Relevance
Currently available therapies have improved survival for patients with advanced ovarian carcinoma, but many patients ultimately relapse and die from their cancer. There is great interest in designing new "individualized" therapeutic regimens based on the specific molecular defects present in a given patient's tumor. Although many drugs and drug combinations are potentially available, identification of the most efficacious of these remains a challenging process that cannot easily be conducted in women with the disease. We have shown the preclinical utility of a genetically engineered mouse model of ovarian carcinoma that closely resembles human endometrioid ovarian cancers with Wnt and PI3K/AktT/mTOR pathway defects for comparison of the activities of multiple drugs targeting activated PI3K/Akt/mTOR signaling. The data suggest the mouse model strategy described here should help accelerate the transition of the most promising new therapies from the laboratory into clinical trials. injection. In 6 of 10 mice euthanized after 3 weeks, micro-320 scopic dysplastic lesions were found exclusively in the 321 injected (right) ovaries (Fig. 1A and B) . Multifocal aggre-322 gates of epithelial cells ("tumorlets"), morphologically 323 indistinguishable from those seen in well-established 324 tumors, were present on the ovarian surface. On the basis 325 of IHC staining, cells in the surface tumorlets were cytoker-326 atin 8-positive (Fig. 1C) and a-inhibin-negative (Fig. 1D ), 327 consistent with epithelial differentiation. As expected, 329 the tumor cells also showed strong nuclear expression of 330 b-catenin (Fig. 1E) and absence of PTEN expression 331 (Fig. 1F) . In 13 mice euthanized 6 weeks post-AdCre 332 injection, 2 had microscopic ovarian tumorlets and 11 had 333 grossly visible, small ovarian tumors (Fig. 1G) ; none 334 had developed ascites or peritoneal metastasis. Microscop-335 ically, the 6-week tumors showed areas of overt glandular 336 differentiation (Fig. 1H ) admixed with more poorly differ-337 entiated and spindle cell areas as observed in the more 338 advanced tumors we described previously (7). Fig. 2A and B) . In 358 Pten flox/flox control mice (n ¼ 47), endometriosis was 359 observed in one AdCre injected ovary. We did not observe 360 tumor formation or endometriosis lesions in any of 361 24 C57BL/6J mice monitored from 3 to 13 months 362 following ovarian bursal AdCre injection. As expected 363 for endometriosis, IHC staining showed strong CK8 pos-364 itivity in the glandular epithelium and scattered CD10-365 positive cells in the adjacent endometriotic stroma 366 (Fig. 2C and D) . Expression of a-inhibin was weak in 367 the stroma relative to the granulosa cells in the ovarian 368 follicles (Fig. 2E) . Importantly, the glandular epithelium 369 showed exclusively membranous staining for b-catenin, 370 indicating absence of Cre-mediated inactivation of 371 Apc, even in the AdCre-injected ovaries (Fig. 2F) . This canonical WNT pathway defects, were also employed for 407 our studies (13). Cells were incubated with different 408 doses of drugs for 24 hours, and data were normalized 409 to vehicle treatment. W2671T cells displayed profound 410 dose-dependent growth inhibition in response to rapa-411 mycin, cisplatin, and paclitaxel ( Fig. 3A-C) . More modest 412 inhibitory effects were observed with perifosine, a syn-414 thetic alkyl phospho-lipid that targets cell membranes 415 and inhibits PKB-mediated AKT activation ( Fig. 3D 
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inhibition of mTORC1 (20, 21). mTORC2, comprised of 447 mTOR, Rictor, mSin1, and mLST8, is relatively resistant to 448 rapamycin. mTORC2 regulates activation of Akt, and 449 mTORC2 activity is stimulated by growth factors such as 450 insulin and insulin growth factor-1 (IGF-1).
451
To further characterize the time and dose-dependent 452 downstream effects of drug-target interactions in vitro, the 453 status of several PI3K/AKT/mTOR signaling pathway com-454 ponents was evaluated in 2 murine OEA-derived cell lines 455 (W2671T, W2830T) before and after rapamycin treatment.
456
As expected, in the absence of drug treatment, W2671T 457 and W2830T cells exhibited constitutive phosphorylation 458 (p) of AKT (Ser473), S6K1 (Thr389), and S6 (Ser235/236).
459
In contrast, there was no or very low level expression 460 of pAKT, pS6K1, and pS6 in ID8 cells, which lack known 461 PI3K/AKT/mTOR and Wnt signaling pathway defects 462 (Fig. 4A) . Levels of p4E-BP1 were similarly low in all 3 cell 464 lines. Several investigators have reported that 100 to 465 1,000 nmol/L rapamycin treatment can inhibit activation 466 of endogenous mTOR (22, 23). Treatment of W2671T and 467 W2830T cells with 100 nmol/L rapamycin more than a 468 24-hour time course showed complete loss of pS6K1 by 469 the 0.5 hours time point and loss of pS6 between 0.5 and 470 4 hours. The timing of pAKT loss in reponse to rapamycin 471 varied between the 2 lines, but pAKT was undetectable in 472 both lines by the 24 hours time point (Fig. 4B) . (Fig. 4C) . In contrast to W2671T cells 485 treated with 100 nmol/L rapamycin (Fig. 4B) , cells treated 486 with 1 nmol/L of rapamycin showed no change in AKT 487 phosphorylation more than a 24-hour time course 488 (Fig. 4D) . At both the 1 nmol/L and 100 nmol/L rapamycin 489 doses, early and sustained decreases in phosphorylation of 490 both S6K1 and S6 were observed ( Fig. 4B and D) . These 491 findings suggest that, in our model system, low doses of 492 rapamycin inhibit only mTORC1, while higher doses are 493 able to inhibit both mTORC1 and mTORC2 in our model 494 system. Interestingly, p4E-BP1 (Thr70) was elevated after 495 2 hours of low-dose (1 nmol/L) rapamycin treatment, 496 peaked at 4 hours, then gradually decreased and was 497 completely inhibited at 24 hours (Fig. 4D ). p4E-BP1 498 (Thr37/46), the form with phosphorylation of the priming 499 sites required for Thr70 phosphorylation, was increased 500 between 0.5 and 16 hours and was nearly undetectable at 501 24 hours (Fig. 4D ). These changes in p4E-BP1 levels were 502 not observed with the high dose (100 nmol/L) of rapamycin 503 (Fig. 4B ). ;Pten flox/flox mice and drug (or 563 vehicle) treatment was initiated after 6 weeks, when all of 564 the mice were expected to have developed at least small 565 tumors based on the studies described above. Data collected 566 after 4 weeks of treatment with rapamycin (2 doses), API-2, 567 perifosine and cisplatin/paclitaxel are shown in Fig. 5A-D , 568 respectively. Treatment with each regimen, including both 569 low (1 mg/kg) and high (4 mg/kg) doses of rapamycin, 570 resulted in statistically significant inhibition of tumor 571 growth more than 4 weeks based on measurements of 572 tumor volume at necropsy. Microscopic analysis of H&E 573 stained sections showed that residual drug-treated tumors 574 were morphologically similar to vehicle-treated tumors 575 (data not shown). None of the drug-treated animals devel-576 oped liver metastases during the treatment period (com-577 pared with 3 of the vehicle-treated mice), and only 2 of 578 36 (6%) drug-treated mice (both in the low-dose rapamycin 579 group) developed ascites, compared with 12 of 33 (36%) 580 vehicle-treated mice. These data are summarized in Table 2 . 
/PTEN
À tumors remaining 614 after 4 weeks of treatment with rapamycin. Only small 615 amounts of tumor tissue remained after treatment, limiting 616 the number of studies that could be done. We found 617 that pS6 (Ser235/236) levels were lower, and pAKT levels 618 slightly increased, in rapamycin-treated tumors compared 619 with those receiving vehicle ( Supplementary Fig. S3 , top 620 panel). IHC staining of residual tumor tissue confirmed 621 significant reduction of pS6 in the rapamycin-treated signaling has been shown to substantially enhance anti-662 tumor effects in vitro and in vivo (31, 32). We tested 663 whether inhibition of AKT signaling in murine and human 664 ovarian cancer cell lines is associated with compensatory 665 upregulation of MEK/ERK signaling. As expected, peri-666 fosine treatment for 2 hours resulted in a dose-dependent 667 reduction of pAKT and pS6 in W2671T, W2830T, and 668 A2780 cells (Fig. 6A and B) . Notably, pERK was also 669 substantially increased in all 3 cell lines following treatment 670 with perifosine. Similar findings were noted in cells treated 671 with API-2, including A2780 cells with and without 672 mutant (S33Y) b-catenin (Fig. 6C and D) . Upregulation of 673 MEK/ERK signaling was also observed in rapamycin treated 674 W2830T and TOV-112D cell lines (Fig. 6E and Supple-675 mentary Fig. S2A ). 
Discussion
